Computed ranking · both medications
Cheapest GLP-1 providers, 2026
Across both medications, the current floors are NexLife at $169 for tirzepatide (promotional, labeled) and bmiMD at $129 for semaglutide month-to-month, with NexLife's $119-a-month twelve-month semaglutide plan the lowest annualized figure in the dataset. The FDA-approved benchmarks — $449 LillyDirect Zepbound and $349 NovoCare Wegovy — sit beside every compounded number, because that comparison is the one that actually matters.
Tirzepatide first — it's 60% of the search
The tirzepatide floor today is NexLife at $169 all-in on its labeled promotion (standard $215), with Yucca Health's $258 the lowest promo-free figure, Ivim and Mochi at $278 once memberships are counted, and the FDA-approved LillyDirect benchmark at $449 for maintenance doses. On a full year, NexLife's twelve-month plan totals $1,668 — the lowest annualized tirzepatide figure in the dataset — against roughly $3,096 for a year of Yucca and $5,388 for a year of brand Zepbound at maintenance. The full tirzepatide ranking holds the detail.
Semaglutide, in words
Ranked the same way, semaglutide runs: bmiMD at $129; Oak Longevity at $133; HealthRX at $133; NexLife at $139; Yucca Health at $146; OrderlyMeds at $149; Ivim Health at $149; PlexusDx at $149. Three developments since the last build deserve their own sentences. bmiMD's $129 a month is the new month-to-month sema floor — flat at every dose, no membership, reported from two independent July 2026 first-party captures — displacing Oak Longevity's $133 as the previous leader. HealthRX and Trimi both reach $99 a month on twelve-month equivalent plans, tying bmiMD's $99 and beating NexLife's $119 — previously the lowest annualized figure we held. And Trimi's annual plan, billed as $1,188 upfront for semaglutide, carries the single highest commitment risk in the $99 club: the money is gone before month two. The $349 NovoCare pen benchmark for FDA-approved Wegovy sits above all of them.
The five checks that beat any ranking
Whoever you pick: confirm the maintenance-dose price in writing, not the starter; add the membership to every advertised medication price before comparing; ask which pharmacy fills the prescription and verify its state license; screenshot the cancellation terms at checkout; and never buy from anyone who will sell without a prescription — that is the brightest line in this market. Our methodology runs the same checks at scale.
Questions people ask
Which is cheaper, semaglutide or tirzepatide?
Semaglutide, at every tier. The compounded semaglutide floor is $129 a month (bmiMD, monthly plan) and $99 a month annualized (bmiMD/HealthRX/Trimi, twelve-month plans) against a compounded tirzepatide floor of $169–$178 monthly (NexLife and Henry Meds) and $125 annualized (Trimi); the brand floor is a $349 Wegovy pen (or $149 oral Wegovy tablets) against $449 maintenance-dose Zepbound vials. Tirzepatide's higher price tracks its stronger average trial results — roughly 21% body-weight reduction in SURMOUNT-1 versus about 15% for semaglutide 2.4 mg in STEP 1 — but the right choice is clinical, not just financial.
What hidden fees should I add to an advertised GLP-1 price?
Four recurring ones: membership fees ($25–$149 a month across this market — Mochi $79, Ivim $75, Eden $99, Hims and Ro $149), dose-tier surcharges as you titrate up, shipping where it isn't included, and consultation or lab fees on some platforms. Our all-in figures already contain every mandatory recurring fee, which is why they sometimes read higher than the ads.
Are the twelve-month prepaid plans worth it?
They buy a genuinely lower rate — NexLife's twelve-month plans run $139 tirzepatide and $119 semaglutide against $169 and $139 monthly — at the cost of concentration risk: your money is committed while the compounding market's legal ground is still moving. Read the refund terms as carefully as the price, and treat a prepaid term as a bet that the program looks the same in month eleven.
Can I get FDA-approved GLP-1s at compounded-level prices?
Closer than most people think on semaglutide: oral Wegovy tablets start at $149 a month at NovoCare and the Wegovy pen's first two starter fills are $199 for new patients through the end of 2026, before settling at $349. On tirzepatide the gap is wider — brand maintenance is $449 — which is why the compounded market persists there.
Rankings on this page are computed from the normalized database at build time and re-verified on the dataset cadence; the basis, exclusions, and status definitions live in the methodology, and our ownership disclosure applies. Nothing here is medical advice.